Beigene Ltd (ADR) (BGNE) Reaches $38.16 After 7.00% Up Move; Irsa Propiedades Comerciales SA (IRCP) Shorts Decreased By 28.57%

May 24, 2017 - By Louis Casey

Irsa Propiedades Comerciales SA (NASDAQ:IRCP) had a decrease of 28.57% in short interest. IRCP’s SI was 500 shares in May as released by FINRA. Its down 28.57% from 700 shares previously. With 7,600 avg volume, 0 days are for Irsa Propiedades Comerciales SA (NASDAQ:IRCP)’s short sellers to cover IRCP’s short positions. The SI to Irsa Propiedades Comerciales SA’s float is 0.03%. About 101 shares traded. IRSA Propiedades Comerciales SA (ADR) (NASDAQ:IRCP) has 0.00% since May 24, 2016 and is . It has underperformed by 16.70% the S&P500.

The stock of Beigene Ltd (ADR) (NASDAQ:BGNE) is a huge mover today! About 52,115 shares traded. Beigene Ltd (ADR) (NASDAQ:BGNE) has risen 36.36% since May 24, 2016 and is uptrending. It has outperformed by 19.66% the S&P500.The move comes after 9 months positive chart setup for the $1.49 billion company. It was reported on May, 24 by Barchart.com. We have $40.83 PT which if reached, will make NASDAQ:BGNE worth $104.30M more.

IRSA Propiedades Comerciales S.A. is a commercial real estate firm in Argentina. The company has market cap of $1.44 billion. The Firm is engaged in the ownership, lease, management, development, operation and purchase of shopping centers and office buildings. It has a 8.71 P/E ratio. It operates through four divisions: Shopping Centers, which includes the results from its commercial exploitation and development of shopping centers, derived from the lease and the provision of services related to the lease of retail stores and other spaces in the shopping centers; Offices and Others, which includes the acquisition, development and management of office buildings and other rental properties in Argentina; Sales and Developments, which includes the results of sales of undeveloped parcels of land and/or trading properties, and Financial Operation and Others, which includes the financial activities carried out by the associate Tarshop S.A.

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The company has market cap of $1.49 billion. The Firm is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It currently has negative earnings. The Firm had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.